In recent years, a new class of weight-loss medications, including Wegovy (semaglutide) and Mounjaro (tirzepatide), has garnered significant attention in the UK. These injectable drugs are now available to certain patients through the NHS and can also be purchased privately, offering a new avenue for managing obesity and related health conditions. Understanding how these medications function is key to appreciating their role in modern healthcare.
At their core, both Wegovy and Mounjaro belong to a class of drugs known as GLP-1 (glucagon-like peptide-1) receptor agonists. GLP-1 is a natural hormone produced in the gut that plays a crucial role in regulating appetite and blood sugar levels. When ingested food reaches the intestines, GLP-1 is released, signalling to the brain that the body is full, thereby reducing hunger. It also stimulates insulin release from the pancreas when blood glucose levels are high and suppresses glucagon, a hormone that raises blood sugar.
Wegovy, which contains semaglutide, primarily mimics the action of GLP-1. By activating GLP-1 receptors in the brain, it helps to reduce appetite and increase feelings of fullness, leading to a reduction in food intake. Additionally, it slows down gastric emptying, meaning food stays in the stomach for longer, further contributing to satiety. Mounjaro, containing tirzepatide, takes this a step further. It is a dual agonist, mimicking not only GLP-1 but also GIP (glucose-dependent insulinotropic polypeptide), another gut hormone involved in appetite and blood sugar regulation. This dual action is thought to provide a more pronounced effect on weight loss and blood sugar control compared to GLP-1 agonists alone.
For patients meeting specific criteria, these medications are available on the NHS. NICE (National Institute for Health and Care Excellence) guidelines recommend Wegovy for adults with a Body Mass Index (BMI) of 35 or above, who also have at least one weight-related comorbidity such as type 2 diabetes or high blood pressure. In some cases, it may be considered for individuals with a BMI of 30-34.9 with a weight-related comorbidity. Mounjaro has recently been approved by NICE for similar indications. These drugs are intended to be used in conjunction with a reduced-calorie diet and increased physical activity, forming part of a comprehensive weight management programme.
Beyond NHS provision, both Wegovy and Mounjaro can be obtained via private prescription in the UK. This option offers greater accessibility for individuals who do not meet the strict NHS criteria or prefer a private route. However, the cost of these medications privately can be substantial, often running into hundreds of pounds per month, which can be a significant barrier for many. Patients considering these treatments, whether via the NHS or privately, should always consult their GP or a qualified healthcare professional to determine suitability and discuss potential side effects.
The introduction and increasing availability of these drugs represent a significant advancement in the medical management of obesity. While they are not a 'miracle cure', they offer a powerful tool to support individuals struggling with weight loss, particularly those with associated health complications. Their mechanism of action, by harnessing the body's natural hunger and satiety signals, provides a targeted approach to weight management that goes beyond traditional dietary restrictions alone.